 Corey Lyon
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 206 | 1.300 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 223 | 1.030 |
Why?
| | Glucocorticoids | 3 | 2018 | 545 | 0.930 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 216 | 0.930 |
Why?
| | Medical Staff | 2 | 2022 | 16 | 0.900 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 66 | 0.900 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 265 | 0.890 |
Why?
| | Hypertension | 3 | 2021 | 1203 | 0.870 |
Why?
| | Metformin | 2 | 2023 | 295 | 0.830 |
Why?
| | Sphygmomanometers | 1 | 2021 | 7 | 0.810 |
Why?
| | Insulin, Isophane | 1 | 2021 | 16 | 0.800 |
Why?
| | Automation | 1 | 2021 | 77 | 0.780 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1137 | 0.780 |
Why?
| | Insulin Glargine | 1 | 2021 | 72 | 0.770 |
Why?
| | Employment | 1 | 2022 | 135 | 0.770 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 360 | 0.760 |
Why?
| | Prediabetic State | 1 | 2023 | 234 | 0.750 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 133 | 0.750 |
Why?
| | Aspirin | 2 | 2020 | 334 | 0.740 |
Why?
| | Preventive Health Services | 1 | 2022 | 135 | 0.740 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 16 | 0.740 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1510 | 0.740 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 21 | 0.740 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 137 | 0.730 |
Why?
| | Humans | 52 | 2023 | 118974 | 0.730 |
Why?
| | Ganglion Cysts | 1 | 2020 | 10 | 0.720 |
Why?
| | Papillomaviridae | 1 | 2020 | 101 | 0.720 |
Why?
| | C-Reactive Protein | 2 | 2021 | 360 | 0.720 |
Why?
| | Wrist | 1 | 2020 | 51 | 0.700 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2174 | 0.680 |
Why?
| | Memory | 1 | 2021 | 230 | 0.680 |
Why?
| | Diuretics | 1 | 2019 | 76 | 0.680 |
Why?
| | Ketorolac | 1 | 2019 | 18 | 0.670 |
Why?
| | Probiotics | 1 | 2019 | 49 | 0.670 |
Why?
| | Glucosamine | 1 | 2018 | 12 | 0.670 |
Why?
| | Erythromycin | 1 | 2018 | 25 | 0.660 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 304 | 0.660 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 12 | 0.650 |
Why?
| | Acute Pain | 1 | 2019 | 33 | 0.650 |
Why?
| | Sweating | 1 | 2018 | 24 | 0.640 |
Why?
| | Glycemic Index | 1 | 2018 | 24 | 0.640 |
Why?
| | Viscosupplements | 1 | 2018 | 10 | 0.640 |
Why?
| | Ureteral Calculi | 1 | 2018 | 13 | 0.630 |
Why?
| | Hot Flashes | 1 | 2018 | 72 | 0.610 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 100 | 0.600 |
Why?
| | Musculoskeletal System | 1 | 2018 | 55 | 0.600 |
Why?
| | Testosterone | 1 | 2021 | 351 | 0.600 |
Why?
| | Patient Education as Topic | 2 | 2022 | 699 | 0.590 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 38 | 0.590 |
Why?
| | Telemedicine | 2 | 2022 | 664 | 0.580 |
Why?
| | Labor, Obstetric | 1 | 2017 | 53 | 0.580 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 168 | 0.580 |
Why?
| | Warfarin | 1 | 2017 | 139 | 0.570 |
Why?
| | Hypoglycemia | 1 | 2021 | 400 | 0.570 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 138 | 0.570 |
Why?
| | Family Practice | 2 | 2018 | 438 | 0.570 |
Why?
| | Analgesics | 1 | 2018 | 159 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1244 | 0.560 |
Why?
| | Job Satisfaction | 1 | 2018 | 175 | 0.560 |
Why?
| | Melatonin | 1 | 2017 | 109 | 0.560 |
Why?
| | Athletic Injuries | 1 | 2023 | 495 | 0.560 |
Why?
| | Migraine Disorders | 1 | 2017 | 79 | 0.560 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 197 | 0.550 |
Why?
| | Brain Concussion | 1 | 2023 | 470 | 0.550 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 29 | 0.550 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1440 | 0.550 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 101 | 0.540 |
Why?
| | Methylprednisolone | 1 | 2016 | 84 | 0.540 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 257 | 0.530 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 628 | 0.520 |
Why?
| | Menopause | 1 | 2018 | 266 | 0.510 |
Why?
| | Cough | 1 | 2015 | 102 | 0.490 |
Why?
| | Mass Screening | 2 | 2022 | 1052 | 0.490 |
Why?
| | Patient Care Team | 2 | 2018 | 521 | 0.490 |
Why?
| | Exercise Therapy | 1 | 2018 | 355 | 0.480 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 143 | 0.460 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 338 | 0.460 |
Why?
| | Antioxidants | 1 | 2017 | 564 | 0.450 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 521 | 0.450 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 19 | 0.450 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 14 | 0.450 |
Why?
| | Anticoagulants | 1 | 2017 | 559 | 0.450 |
Why?
| | Virus Diseases | 1 | 2015 | 198 | 0.440 |
Why?
| | Behavior Therapy | 3 | 2023 | 237 | 0.440 |
Why?
| | Low Back Pain | 2 | 2023 | 100 | 0.400 |
Why?
| | Health Promotion | 1 | 2018 | 691 | 0.400 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 1798 | 0.400 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6561 | 0.380 |
Why?
| | Pain Measurement | 4 | 2023 | 469 | 0.370 |
Why?
| | Aged | 10 | 2021 | 19657 | 0.350 |
Why?
| | Depression | 1 | 2017 | 1132 | 0.340 |
Why?
| | Female | 16 | 2023 | 61565 | 0.330 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 125 | 0.320 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 221 | 0.310 |
Why?
| | Pregnancy | 4 | 2022 | 5691 | 0.310 |
Why?
| | Middle Aged | 11 | 2021 | 27617 | 0.300 |
Why?
| | Organizational Innovation | 2 | 2019 | 138 | 0.300 |
Why?
| | Abdomen, Acute | 1 | 2006 | 20 | 0.290 |
Why?
| | Azithromycin | 2 | 2018 | 81 | 0.290 |
Why?
| | Treatment Outcome | 7 | 2021 | 9342 | 0.280 |
Why?
| | Enuresis | 1 | 2005 | 4 | 0.280 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.270 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 11 | 0.270 |
Why?
| | Adult | 8 | 2021 | 31512 | 0.250 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 80 | 0.240 |
Why?
| | Fibromyalgia | 1 | 2023 | 56 | 0.220 |
Why?
| | Age Factors | 2 | 2022 | 2995 | 0.220 |
Why?
| | Naltrexone | 1 | 2023 | 80 | 0.220 |
Why?
| | Electronics | 1 | 2023 | 76 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 1945 | 0.210 |
Why?
| | Occult Blood | 1 | 2022 | 27 | 0.210 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 693 | 0.210 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.200 |
Why?
| | Postmenopause | 1 | 2023 | 305 | 0.200 |
Why?
| | Life Style | 1 | 2023 | 430 | 0.200 |
Why?
| | Fish Oils | 1 | 2020 | 25 | 0.190 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 39 | 0.190 |
Why?
| | Time Factors | 2 | 2023 | 6412 | 0.190 |
Why?
| | United States | 4 | 2022 | 12555 | 0.190 |
Why?
| | Labor Stage, Second | 1 | 2020 | 4 | 0.190 |
Why?
| | Prenatal Care | 1 | 2022 | 252 | 0.190 |
Why?
| | Colonoscopy | 1 | 2022 | 208 | 0.180 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 67 | 0.180 |
Why?
| | Pain Management | 2 | 2023 | 294 | 0.170 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 125 | 0.170 |
Why?
| | Male | 9 | 2021 | 57801 | 0.170 |
Why?
| | Systems Integration | 1 | 2018 | 42 | 0.170 |
Why?
| | Ticlopidine | 1 | 2019 | 61 | 0.170 |
Why?
| | Primary Health Care | 2 | 2019 | 1560 | 0.170 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 301 | 0.160 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 35 | 0.160 |
Why?
| | Clostridium Infections | 1 | 2019 | 57 | 0.160 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 12 | 0.160 |
Why?
| | Netherlands | 1 | 2018 | 62 | 0.160 |
Why?
| | Primary Prevention | 1 | 2020 | 185 | 0.160 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 98 | 0.160 |
Why?
| | Citalopram | 1 | 2018 | 27 | 0.160 |
Why?
| | Arthralgia | 1 | 2018 | 51 | 0.160 |
Why?
| | Visual Analog Scale | 1 | 2018 | 31 | 0.160 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 37 | 0.160 |
Why?
| | Yoga | 1 | 2018 | 27 | 0.160 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 110 | 0.160 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 62 | 0.160 |
Why?
| | Patients | 1 | 2019 | 175 | 0.150 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 143 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 117 | 0.150 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.150 |
Why?
| | Dietary Supplements | 1 | 2020 | 467 | 0.150 |
Why?
| | Recurrence | 1 | 2020 | 975 | 0.150 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 44 | 0.150 |
Why?
| | Sleep | 1 | 2022 | 660 | 0.140 |
Why?
| | Regression Analysis | 1 | 2019 | 983 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 387 | 0.140 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 44 | 0.140 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 67 | 0.140 |
Why?
| | Pain | 2 | 2023 | 735 | 0.140 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 248 | 0.140 |
Why?
| | Burnout, Professional | 2 | 2019 | 330 | 0.140 |
Why?
| | Exanthema | 1 | 2016 | 77 | 0.140 |
Why?
| | Hemorrhage | 1 | 2020 | 623 | 0.140 |
Why?
| | Prednisone | 1 | 2016 | 235 | 0.140 |
Why?
| | Administration, Oral | 1 | 2018 | 756 | 0.130 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 402 | 0.130 |
Why?
| | Injections | 1 | 2016 | 167 | 0.130 |
Why?
| | Diabetic Foot | 1 | 2015 | 23 | 0.130 |
Why?
| | Psychiatry | 1 | 2018 | 201 | 0.130 |
Why?
| | Acute Disease | 1 | 2018 | 940 | 0.130 |
Why?
| | Health Status | 1 | 2020 | 726 | 0.130 |
Why?
| | Achilles Tendon | 1 | 2015 | 45 | 0.130 |
Why?
| | Young Adult | 2 | 2023 | 10793 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2019 | 586 | 0.120 |
Why?
| | Sulfonamides | 1 | 2018 | 445 | 0.120 |
Why?
| | Pandemics | 1 | 2022 | 1355 | 0.120 |
Why?
| | Tendon Injuries | 1 | 2015 | 80 | 0.120 |
Why?
| | Gestational Age | 1 | 2017 | 765 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2018 | 1687 | 0.120 |
Why?
| | Treatment Failure | 1 | 2015 | 341 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 234 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 965 | 0.120 |
Why?
| | Psychometrics | 1 | 2017 | 631 | 0.120 |
Why?
| | Osteomyelitis | 1 | 2015 | 110 | 0.120 |
Why?
| | Administration, Inhalation | 1 | 2015 | 656 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2020 | 762 | 0.110 |
Why?
| | Colorado | 2 | 2019 | 4196 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 38 | 0.100 |
Why?
| | Mental Disorders | 1 | 2018 | 939 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 1032 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1865 | 0.080 |
Why?
| | Prospective Studies | 1 | 2018 | 6471 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4708 | 0.070 |
Why?
| | Adolescent | 1 | 2023 | 18480 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 294 | 0.060 |
Why?
| | Amitriptyline | 1 | 2023 | 21 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3174 | 0.060 |
Why?
| | Trigger Points | 1 | 2023 | 14 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1384 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 9 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 969 | 0.050 |
Why?
| | Long-Term Care | 1 | 2019 | 74 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 146 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 148 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 191 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 736 | 0.040 |
Why?
| | Skin | 1 | 2020 | 657 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1267 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 34 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 105 | 0.030 |
Why?
| | Child | 2 | 2022 | 19129 | 0.030 |
Why?
| | Mental Health Services | 1 | 2018 | 331 | 0.030 |
Why?
| | Foot | 1 | 2015 | 106 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1527 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 554 | 0.030 |
Why?
| | Blood Glucose | 1 | 2022 | 1939 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2326 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 861 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 3443 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 963 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1795 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1664 | 0.020 |
Why?
| | Infant | 1 | 2022 | 8293 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 9000 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|